Methods for treating or limiting development of cardiovascular disease-related neurological disorders

A method for treating a cardiovascular disease-related neurological disorder in a subject having a cardiovascular disease-related neurological disorder, or for limiting development of a cardiovascular disease-related neurological disorder in a subject having a cardiovascular disease who is at risk of developing a neurological disorder, comprising administering to a said subject an amount effective to treat the cardiovascular disease-related neurological disorder of compound of general formula I:

• wherein:
• ring A is a five-membered or six-membered heteroaryl or heterocyclyl ring containing either a combination of two non-adjacent nitrogen or oxygen atoms, or a combination of three or four nitrogen or oxygen atoms;
• ring B is a five-membered or six-membered heteroaryl ring that contains at least one nitrogen atom;
• ring C is an optionally substituted aryl ring;
• A1, A2, A3, A4 are independently selected from a group consisting of ═N—, —C(═O)—, —C(Ra)═, ═C(Rb)—, —C(Rc)(Rd)—N(Rc)—, —C(Rc)(Rd)—O—, or —[C(Rc)(Rd)]n— with n being 1 or 2;
• X1—X2 is (R6)C—N, N—C(R6), N—N, N—O, O—N, N—S or S—N;
• X3 is (R7)C═C(R8), O, S, or N(R9);
• Z is O, NH or a bond to R5;
• Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, hydroxyalkyl, alkoxyalkyl, alkoxy, aryloxy, formyl, acyl, acylamido or carboxy, provided that Ra and Rb can also join to form a ring of up to 6 atoms;
• Rc and Rd are independently selected from a group consisting of hydrogen, alkyl, aryl, or heteroaryl, provided that Rc and Rd can also join to form a ring of up to 6 atoms;
• Re is hydrogen, alkyl, aryl, heteroaryl, acyl, alkoxyacyl, aminoacyl, dialkylaminoacyl, or dialkylaminoacyl;
• R1, R3, R4, R6, R7, and R8 are independently selected from a group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylmethyl, heteroarylmethyl, fluoro, bromo, iodo, cyano, hydroxy, amino, alkylamino, alkoxy, aryloxy, alkoxyalkyl, or aryloxyalkyl;
• R2 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylmethyl, heteroarylmethyl, alkoxy, trifluoromethoxy, perfluoroalkoxy, aryloxy, alkoxyalkyl, or aryloxyalkyl;
• R5 is alkyl, aryl, heteroaryl, hydroxyalkyl, carboxyalkyl, alkoxyalkyl, or aryloxyalkyl;
• and
• R9 is hydrogen, alkyl, aryl, heteroaryl, acyl, alkoxyacyl, aminoacyl, dialkylaminoacyl, or dialkylaminoacyl.
• or a pharmaceutically acceptable salt thereof.